|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
ORAL CONTRACEPTIVES EFFICACY IS REDUCED
|
CO-ADMINISTRATION OF CELECOXIB WITH DRUGS KNOWN TO INHIBIT CYP4502C9, SUCH AS AMIODARONE, MAY RESULT IN INCREASED PLASMA CONCENTRATION ; CAUTION SHOULD BE EXERCISED IF USED CONCURRENTLY
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
ANTAGONISM BETWEEN AMPHOTERICIN B AND IMIDAZOLE DERIVATIVES, WHICH INHIBIT ERGOSTEROL SYNTHESIS, HAS BEEN REPORTED ; CLINICAL SIGNIFICANCE OF THIS FINDING HAS NOT BEEN DETERMINED
|
CO-ADMINISTRATION MAY RESULT IN INCREASED BUSULFAN TOXICITY
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
OMEPRAZOLE & OTHER ANTISECRETORY DRUGS REDUCE ABSORPTION OF THE DRUG
|
OMEPRAZOLE & OTHER ANTISECRETORY DRUGS REDUCE ABSORPTION OF THE DRUG
|
OMEPRAZOLE & OTHER ANTISECRETORY DRUGS REDUCE ABSORPTION OF THE DRUG
|
OMEPRAZOLE & OTHER ANTISECRETORY DRUGS REDUCE ABSORPTION OF THE DRUG
|
OMEPRAZOLE & OTHER ANTISECRETORY DRUGS REDUCE ABSORPTION OF THE DRUG
|
CLARITHROMYCIN INCREASES PLASMA CONCENTRATION BY 30% AND MEAN HALF LIFE FROM 1.2 TO 1.6 HRS
|
IMIDAZOLE ANTIFUNGALS INCREASE SERUM CONC OF PHENYTOIN WHILE PHENYTOIN DECREASE PLASMA LEVELS OF ANTIFUNGALS
|
RIFAPENTINE INDUCES METABOLISM OF THE OTHER DRUG CAUSING DECREASED PLASMA LEVELS
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCURRENT USE WITH TERFENADINE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF IT; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS, LIKE PROLONGED QT INTERVAL,CARDIAC ARREST,TORSADE DE POINTES,VENTRICULAR ARRHYTHMIAS, AND DEATH HAVE BEEN REPORTED
|
ERYTHROMYCIN INCREASES PLASMA CONCENTRATION OF THE DRUG DUE TO REDUCED CLEARANCE
|
ERYTHROMYCIN INCREASES PLASMA CONCENTRATION OF THE DRUG DUE TO REDUCED CLEARANCE
|
ERYTHROMYCIN INCREASES PLASMA CONCENTRATION OF THE DRUG DUE TO REDUCED CLEARANCE
|
ERYTHROMYCIN INCREASES PLASMA CONCENTRATION OF THE DRUG DUE TO REDUCED CLEARANCE
|
INDINAVIR MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
INDINAVIR MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
CYTOCHROME P450 INHIBITORS MAY INHIBIT 25 HYDROXYLATION OF DOXERCALCIFEROL, HENCE FORMATION OF ACTIVE MOITY MAY BE HINDERED
|
DAPOXETINE DOSE IS RESTRICTED TO 30 MG DUE TO POSSIBILITY OF INCREASED SIDE EFFECTS ON COADMINISTRATION
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
CO-ADMINISTRATION WITH KETOCONAZOLE MAY RESULT IN REDUCED CAFFEINE ELIMINATION ; LOWER DOSES OF CAFFEINE MAY BE NEEDED
|
CO-ADMINISTRATION OF DIGOXIN WITH ITRACONAZOLE RAISES THE SERUM DIGOXIN CONCENTRATION DUE TO REDUCTION IN CLEARANCE AND/OR IN VOLUME OF DISTRIBUTION OF THE DRUG WITH IMPLICATION THAT DIGITALIS TOXICITY MAY RESULT
|
CO-ADMINISTRATION OF DIGOXIN WITH ITRACONAZOLE RAISES THE SERUM DIGOXIN CONCENTRATION DUE TO REDUCTION IN CLEARANCE AND/OR IN VOLUME OF DISTRIBUTION OF THE DRUG WITH IMPLICATION THAT DIGITALIS TOXICITY MAY RESULT
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
CONCURRENT USE WITH ASTEMIZOLE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
ANTIMUSCARINICS CONCURRENT ADMINISTRATION MAY REDUCE INTESTINAL MOTILITY AND ABSORPTION OF OTHER DRUG
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|